SUSTAIN 6 was designed to assess non-inferiority, i.e. demonstrate no increased risk of major CV events vs placebo, when added to standard of care. no dataSuperiority testing was not part of the pre-specified analysis. The primary endpoint was the first occurrence of a composite CV outcome comprising CV death, non-fatal myocardial infarction or non-fatal stroke. About the SUSTAIN clinical programme SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical programme for semaglutide, administered once-weekly, that comprises six phase 3a global clinical trials encompassing more than 7,000 adults with type 2 diabetes as well as two Japanese trials encompassing around 1,000 adults with type 2 diabetes. About Novo Nordisk Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Recognising Fast Solutions In Eye Bags | Charles Rivera TravelHeadquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com , Facebook , Twitter , LinkedIn , YouTube . Further information _______________________ References Marso SP, Bain S, Consoli A,et al. Semaglutide and cardiovascular outcomes, efficacy and safety in type 2 diabetes.New England Journal of Medicine.2016; In Press.
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/semaglutide-reduced-major-cardiovascular-events-by-26-in-adults-with-type-2-diabetes-at-high-cardiovascular-risk-593658161.html